We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
In the latest trading session, Bristol Myers Squibb (BMY - Free Report) closed at $57.27, marking a +1.18% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 2.65%. Elsewhere, the Dow saw a downswing of 1.35%, while the tech-heavy Nasdaq depreciated by 4.18%.
The biopharmaceutical company's shares have seen an increase of 0.62% over the last month, not keeping up with the Medical sector's gain of 3.33% and the S&P 500's gain of 5.47%.
The investment community will be paying close attention to the earnings performance of Bristol Myers Squibb in its upcoming release. In that report, analysts expect Bristol Myers Squibb to post earnings of $1.61 per share. This would mark year-over-year growth of 10.27%. At the same time, our most recent consensus estimate is projecting a revenue of $11.67 billion, reflecting a 4.89% fall from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $6.32 per share and revenue of $47.39 billion, indicating changes of +2.76% and -1.67%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Bristol Myers Squibb. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.38% upward. Bristol Myers Squibb is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, Bristol Myers Squibb is holding a Forward P/E ratio of 8.95. This represents a discount compared to its industry average Forward P/E of 20.92.
It is also worth noting that BMY currently has a PEG ratio of 0.16. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.51 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 148, finds itself in the bottom 40% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know
In the latest trading session, Bristol Myers Squibb (BMY - Free Report) closed at $57.27, marking a +1.18% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 2.65%. Elsewhere, the Dow saw a downswing of 1.35%, while the tech-heavy Nasdaq depreciated by 4.18%.
The biopharmaceutical company's shares have seen an increase of 0.62% over the last month, not keeping up with the Medical sector's gain of 3.33% and the S&P 500's gain of 5.47%.
The investment community will be paying close attention to the earnings performance of Bristol Myers Squibb in its upcoming release. In that report, analysts expect Bristol Myers Squibb to post earnings of $1.61 per share. This would mark year-over-year growth of 10.27%. At the same time, our most recent consensus estimate is projecting a revenue of $11.67 billion, reflecting a 4.89% fall from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $6.32 per share and revenue of $47.39 billion, indicating changes of +2.76% and -1.67%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Bristol Myers Squibb. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.38% upward. Bristol Myers Squibb is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, Bristol Myers Squibb is holding a Forward P/E ratio of 8.95. This represents a discount compared to its industry average Forward P/E of 20.92.
It is also worth noting that BMY currently has a PEG ratio of 0.16. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.51 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 148, finds itself in the bottom 40% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.